60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives “Sell (E+)” Rating from Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reaffirmed by equities research analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Tuesday, February 25th.

60 Degrees Pharmaceuticals Stock Down 10.6 %

NASDAQ SXTP opened at $1.77 on Friday. 60 Degrees Pharmaceuticals has a 52-week low of $1.41 and a 52-week high of $35.99. The business’s 50-day moving average price is $2.86 and its 200 day moving average price is $4.78. The firm has a market cap of $2.61 million, a P/E ratio of -0.18 and a beta of 4.52.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.